Lung Cancer Interception/INTIME Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Lung Cancer Interception/INTIME Dream Team

SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team:
Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)

Grant Term: March 2018–February 2022

With innovative technologies and unique patient populations, the SU2C–LUNGevity Foundation–American Lung Association (ALA) Lung Cancer Interception Dream Team seeks to understand how early lung cancer develops and is testing methods to block this development using several complementary approaches. The insights gained from this team’s work will enable the medical and research communities to make major strides in the effort to thwart lung cancer before it occurs.

ABOUT THIS TEAM’S RESEARCH

Lung cancer is the leading cause of cancer death in the United States and worldwide. The SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team proposes several complementary strategies to help prevent patients from developing lung cancer.

The team is working to create an atlas of precancer of the lung that can help identify the types of cancerous lung tissue that will require aggressive treatment. The team is also attempting to identify treatments that can prevent these abnormal lesions from progressing to invasive lung cancer.

In addition, the researchers are developing two sets of diagnostic tools that will be able to detect lung cancer early. The first set involves using nasal swabs and imaging to confirm whether lung abnormalities found in chest images are lung cancer or benign lung characteristics. The second set involves the use of blood tests to identify patients at the earliest stages of lung cancer recurrence.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.